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390Objective: Anatomic segmentectomy may achieve results comparable to lobectomy for early-stage non–small
cell lung cancer. The 7th edition of the AJCC Cancer Staging Handbook stratified the previous T1 tumor des-
ignation into T1a and T1b subsets, which still define stage 1A node-negative non–small cell lung cancer. We are
left to hypothesize whether this classification may aid in directing the extent of surgical resection. We retrospec-
tively reviewed our anatomic segmentectomy and lobectomy management of stage 1A non–small cell lung can-
cer to determine differences in survival and local recurrence rates based on the new stratification.
Methods: We performed a retrospective review of 429 patients undergoing resection of pathologically con-
firmed stage 1A non–small cell lung cancer via lobectomy or anatomic segmentectomy. Primary outcome vari-
ables included mortality, recurrence, and survival. Recurrence-free and cancer-specific survivals were estimated
using the Kaplan–Meier method.
Results: Patients undergoing segmentectomy were older than patients undergoing lobectomy (mean age 69.2 vs
66.8 years, P<.006). The mean preoperative forced expiratory volume in 1 second was significantly lower in the
segmentectomy group than in the lobectomy group (71.8% vs 81.1%, P¼ .02). Mortality was similar after seg-
mentectomy (1.1%) and lobectomy (1.2%). There was no difference in mortality, recurrence rates (14.0% vs
14.7%, P ¼ 1.00), or 5-year cancer-specific survival (T1a: 90% vs 91%, P ¼ .984; T1b: 82% vs 78%,
P ¼ .892) when comparing segmentectomy and lobectomy for pathologic stage 1A non–small cell lung cancer,
when stratified by T stage.
Conclusions: Anatomic segmentectomy may achieve equivalent recurrence and survival compared with
lobectomy for patients with stage 1A non–small cell lung cancer. Prospective studies will be necessary to
delineate the potential merits of anatomic segmentectomy in this setting. (J Thorac Cardiovasc Surg
2012;143:390-7)The new international lung cancer staging system is the cul-
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The Journal of Thoracic and Cardiovascular SurgLung Cancer have led to a comprehensive, detailed staging
system.1,2 The cooperation of the International Union
Against Cancer and American Joint Committee on Cancer
(AJCC) resulted in the publication of a uniform staging
manual accepted worldwide: the 7th edition of the AJCC
Cancer Staging Handbook.3
Although lobectomy is considered bymany surgeons to be
the first line of therapy for stage 1 non–small cell lung cancer
(NSCLC),4 a growing body of evidence suggests an accept-
able and possible preferable role of anatomic segmentectomy
for the definitive management of small peripheral stage I
NSCLC.5-7 Use of sublobar resection, preferably anatomic
segmentectomy, in lieu of lobectomy for the management
of otherwise resectable stage 1 NSCLC identified in
patients of advanced age or with impaired cardiopulmonary
reserve is also a reasonable resection consideration.5-11
The 7th edition of the AJCC Cancer Staging Handbook
for NSCLC has subdivided stage 1A tumors (3 cm) into
2 subsets: T1a (2 cm) and T1b (>2 cm and 3 cm).3 By
using this new stage 1A subclassification system, we ana-
lyzed the clinical outcomes of patients with pathologically
confirmed stage 1A NSCLC who underwent R0 resectionery c February 2012
TABLE 1. Patient demographics and operative data by T descriptor
T1a (n ¼ 284) T1b (n ¼ 145) P value
Age, y
Mean 67.0 69.4 .009
Range 28–88 43–88
Gender 123 male, 161 female 75 male, 70 female .10
Operation
Segmentectomy 121 (42.6%) 57 (39.3%) .54
Lobectomy 163 (57.4%) 88 (60.7%)
Approach
VATS 142 (50.0%) 62 (42.8%) .18
Open 142 (50.0%) 83 (57.2%)
VATS, Video-assisted thoracoscopic surgery.
TABLE 2. Resections performed
Location No. of resections performed
Right upper lobe 99
Anterior 8
Posterior 18
Apical 11
Apico-posterior 8
Right middle lobe 12
Medial/lateral 19
Right lower lobe 39
Superior 21
Basilar 12
Left upper lobe 68
Upper division 43
Lingula 14
Left lower lobe 33
Superior 13
Basilar 11
Abbreviations and Acronyms
AJCC ¼ American Joint Committee on Cancer
FEV1 ¼ forced expiratory volume in 1 second
NSCLC ¼ non–small cell lung cancer
VATS ¼ video-assisted thoracoscopic surgery
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Sby anatomic segmentectomy or lobectomy from 2002 to
2009. Our goals were to determine whether differences
could be determined in recurrence and survival patterns be-
tween patients with stage 1A NSCLC definitively managed
by anatomic segmentectomy or lobectomy based on the new
stratification in the T stage: T1a and T1b.
PATIENTS AND METHODS
Patient Selection and Surgical Approach
This study was reviewed and approved by the institutional review board
of the University of Pittsburgh (No. PRO009120047), and individual pa-
tient consent was waived given the retrospective nature of the analysis.
A total of 429 consecutive patients with anatomic pulmonary resection
for pathologically confirmed stage 1A NSCLC from 2002 to 2009 were
identified by the Thoracic Tumor Registry and from the billing records
of the Heart, Lung, and Esophageal Surgery Institute of the University of
Pittsburgh Medical Center. Only patients with pathologic stage 1A disease
were included in this study (Table 1). Lobectomywas performed in 251 pa-
tients, by thoracotomy in 152 and video-assisted thoracoscopic surgery
(VATS) in 99. Anatomic segmentectomy was performed in 178 patients.
Of these patients, 73 underwent open segmentectomy and 105 patients un-
derwent anatomic segmentectomy via a VATS approach. All patients un-
derwent careful preoperative staging with computed tomography scan
(with or without positron emission tomography) within 6 weeks of surgery
and pulmonary function testing. Positron emission tomography scanning
was not routinely performed in this cohort of patients with early-stage dis-
ease but was selectively used according to tumor size and location, evi-
dence for mediastinal lymph node enlargement on computed tomography
imaging, and physician judgment. Mediastinoscopy was performed in pa-
tients with enlarged mediastinal lymph nodes (>1 cm in diameter) or in pa-
tients with positive FDG uptake on positron emission tomography
scanning. A total of 21 of 178 patients (11.8%) in the segmentectomy
group and 50 of 251 patients (19.9%) in the lobectomy group underwent
mediastinoscopy. All patients were staged on final pathologic review as
stage 1A according to the TNM classification of the American Joint Com-
mittee for Cancer Staging and the Revised International System for staging
lung cancer.3
Operative Technique and Hospital Course
Thoracotomy was performed in 225 patients (52.4%), with a VATS ap-
proach used in 204 patients (47.6%). All of the principal anatomic seg-
ments were resected (Table 2). The largest determinants in selecting
a patient for segmentectomy were limited functional status, comorbidities,
and surgeon judgment regarding resectability using a segmental approach.
However, with time, even patients with good pulmonary function were con-
sidered for segmentectomy as long as anatomic considerations were still fa-
vorable. Open segmental resection was performed by muscle-sparing
axillary thoracotomy or posterolateral thoracotomy. The VATS approach
was performed as described previously.7 Anatomic segmentectomy was
performed with individual isolation and division of the corresponding ar-
tery and bronchus. In addition, an extended parenchymal margin was ob-
tained during stapling, which carried the line of division into theThe Journal of Thoracic and Caadjacent segmental parenchyma (extended segmentectomy). We prefer
the stapled, extended approach to segmentectomy, which serves to incorpo-
rate the corresponding intersegmental veins (rather than a selective dissec-
tion and identification of the intersegmental veins) to minimize the risk of
bleeding and prolonged postoperative air leaks.4 Systematic mediastinal
lymph node sampling is performed during the course of resection. Patients
were typically monitored in the intensive care unit overnight and trans-
ferred to the floor the following day. Chest tube management and discharge
planning were individualized on the basis of patient clinical characteristics
and surgeon judgment. Chest tubes were usually removed when air leaks
ceased and drainage decreased to less than 250 mL/day. Patients were dis-
charged after chest tube removal when clinically stable. In cases of pro-
longed air leaks, patients were discharged after placing a Heimlich valve
and ensuring stability of lung expansion. Discharge criteria were not influ-
enced by clinical pathways or type of surgery performed.
Follow-up
Perioperative and follow-up data were collected from the hospital chart,
anesthesia, and operating room records, as well as the electronic medical
record for each patient. All patients were followed postoperatively at 2
weeks, at 4- to 6-month intervals for the first 2 years, and yearly thereafter
with computed tomography scans. Locoregional recurrence was defined as
evidence of tumor within the same lobe, the hilum, or the mediastinal
lymph nodes. Distant recurrences were defined as evidence of tumor in an-
other lobe or elsewhere outside the hemithorax. In addition to the data de-
rived from the electronic medical record and the University of Pittsburghrdiovascular Surgery c Volume 143, Number 2 391
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SLung Cancer Registry, mortality data were obtained from the Social
Security Death Index. The primary end points for this analysis were peri-
operative outcomes, morbidity and mortality rates, and disease-free and
cancer-specific survival. Perioperative mortality was defined as any patient
who died within the first 30 days after surgery. Mean follow-up was 45.3
months for the entire group of patients with stage 1A NSCLC (segmentec-
tomy, 39.6 months; lobectomy, 50.9 months).
Statistical Analysis
Statistical analyses were performed using the Statistical Package for the
Social Sciences 17.0 (SPSS Inc, Chicago, Ill). The lobectomy and segmen-
tectomy groups, based on T stage, were compared with the nonparametric
Wilcoxon test for continuous variables and Fisher exact test for categoric
variables. Disease-free and overall survival analyses were carried out by
means of the Kaplan–Meier approach (log-rank test). All comparisons
were 2-tailed. Recurrence-free survival was defined as the time from sur-
gery to the first diagnosis of local, regional, or distant disease recurrence
or to the last-follow-up. Cancer-specific survival was defined as overall
time of survival to death or last follow-up based on the presence or absence
of cancer at the time of death.
RESULTS
Demographic and Group Characteristics
The average age of all patients was 67.8 years. The mean
agewas67.0 years for patientswithT1a tumors and69.4years
for patients with T1b tumors (P ¼ .009) (Table 1). The
average tumor size was 1.8  0.7 cm for all patients. The
mean tumor size was 1.4  0.4 cm for T1a tumors and 2.6TABLE 3. Segmentectomy versus lobectomy for stage 1A tumors
Segmentectomy (n ¼ 178)
Comorbidities (%)
Coronary artery disease 18.5
Hypertension 28.1
Diabetes 11.2
COPD 26.4
Pulmonary function tests (preoperative)
FEV1  SD (%) 71.8  25.6
Range (15%–114%)
DLCO  SD (%) 65.4  22.4
Range (15%–135%)
Approach (%)
VATS 59.0
Open 41.0
Histology (%)
Adenocarcinoma 51.7
Squamous 36.5
Bronchoalveolar 5.1
Other 6.7
Differentiation (%)
Well 12.9
Moderately 60.1
Poorly 27.0
Angiolymphatic invasion (%) 22.5
LN harvested (median) 5
LN stations sampled (median) 4
Mortality (30 d) 2 (1.1%)
COPD, Chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second
assisted thoracoscopic surgery; LN, lymph node.
392 The Journal of Thoracic and Cardiovascular Surg 0.3 cm for T1b tumors. The mean surgical margin was
1.9 cm for segments and 2.0 for lobes. All typically resected
lobes and segments were represented in the groups (Table 2).
Segmentectomy Versus Lobectomy for T1a and T1b
Tumors
Table 3 summarizes the patient populations who under-
went lobectomy or segmentectomy. A total of 429 patients
with stage 1A NSCLC underwent anatomic resection.
There were 251 lobectomies, of which 99 were VATS and
152 were open lobectomies. In addition, 178 patients under-
went anatomic segmentectomy, by a thoracoscopic ap-
proach in 105 and an open approach in 73. An open
approach was more commonly used with lobectomy than
with segmentectomy (60.6% vs 41.0%, P ¼ .0001).
Patients undergoing segmentectomy were more likely to
have coronary artery disease (18.5% vs 12.8%, P ¼ .036)
or chronic obstructive pulmonary disease (26.4% vs
14.4%, P ¼ .0001) compared with lobectomy. Patients un-
dergoing segmentectomy also had significantly worse
forced expiratory volume in 1 second (FEV1) compared
with those undergoing lobectomy (81.1  17.6 vs 71.8 
25.6, P ¼ .02). Other comorbid conditions were not signif-
icantly different between patients undergoing lobectomy
and segmentectomy (Table 3).Lobectomy (n ¼ 251) P value
12.8 .036
27.2 .4
9.7 .4
14.4 .0001
81.1  17.6 .02
(58%–119%)
70.7  17.7 .4
(35%–170%)
39.4 .0001
60.6
55.0 .56
30.3 .18
8.0 .33
6.7 1.00
13.1 1.00
64.1 .42
22.7 .36
21.5 .81
12 <.001
4 1.00
3 (1.2%) 1.00
; SD, standard deviation;DLCO, diffusion capacity for carbon monoxide; VATS, video-
ery c February 2012
FIGURE 1. Recurrence-free survival of all patients undergoing resection
of pathologic stage 1A NSCLC (red). A significant difference in survival is
noted when comparing T1a (blue) and T1b (green) tumors (P ¼ .027).
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SAs expected, lobectomywas associated with significantly
more lymph nodes examined compared with segmentec-
tomy (median, 12 vs 5; P< .0001). However, there was
no difference in the number of lymph node stations sampled
(median of 4 for both segments and lobes). For T1a tumors,
the margin distance:tumor size ratio was 1.52  1.18 for
segmentectomy and 1.63  1.28 for lobectomy (P ¼ .58).
For T1b tumors, the margin distance:tumor size ratio was
0.71  049 after segmentectomy and 0.80  0.70
(P ¼ .54) after lobectomy. These data suggest that theFIGURE 2. Recurrence-free survival for T1a and T1b tumo
The Journal of Thoracic and Camargin:tumor ratio was similar whether performing an ana-
tomic segmentectomy or lobectomy for T1a or T1b tumors.
Overall mortality was 1.1% for segments and 1.2% for
lobes.Recurrence and Survival
The mean follow-up in this study was 45.3 months.
For all patients undergoing resection, the estimated
recurrence-free survival was 82% at 60months.When eval-
uated by T stage, patients with T1a tumors had an 86%
recurrence-free survival, whereas patients with T1b tumors
had an estimated 78% 5-year survival (P¼ .027) (Figure 1).
Recurrence-free survival for those with T1a and T1b tumors
stratified by operation type is shown in Figure 2. There was
no difference in recurrence-free survival after segmentec-
tomy or lobectomy for those with T1a (P ¼ .757) or T1b
(P ¼ .423) tumors (Figure 3). When analyzing patterns of
recurrence, there was no significant difference in locore-
gional or distant recurrence for T1a or T1b tumors
(Table 4). Mean time to recurrence was 23 months among
all patients. There was an approximately 2:1 ratio of distant
to locoregional recurrence noted. Brachytherapy mesh was
used in 54 of 178 patients (30.3%) undergoing segmentec-
tomy. The use of brachytherapy mesh was not associated
with any discernible difference in locoregional (5.6% vs
5.6%), distant (9.3 vs 8.9%), or overall (14.8% vs
14.5%) recurrence rates compared with patients undergo-
ing segmentectomy without mesh (P ¼ 1.00).
When considering deaths related to cancer, there was no
significant difference in cancer-specific survival when
comparing segmentectomy with lobectomy for T1a orrs stratified by segmentectomy (A) and lobectomy (B).
rdiovascular Surgery c Volume 143, Number 2 393
FIGURE 3. Recurrence-free survival curves comparing outcomes after segmentectomy or lobectomy for T1a (A) and T1b (B) tumors.
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ST1b tumors (Figure 4). Of note, segmentectomies were as-
sociated with a significantly increased rate of non–cancer-
related deaths compared with lobectomy, 79% versus
56%, respectively (P ¼ .0065), perhaps because patients
undergoing segmentectomy had greater preoperative co-
morbidity (coronary artery disease, chronic obstructive pul-
monary disease, decreased FEV1) when compared with
those undergoing lobectomy (Figure 4).DISCUSSION
Many patients referred to the thoracic surgeon are sent
for definitive management of the small peripheral pulmo-
nary lesion highly suspicious for carcinoma or with a previ-
ous image-guided diagnosis of lung cancer. On review ofTABLE 4. Recurrence and survival patterns
Segmentectomy
(n ¼ 121)
Lobectomy
(n ¼ 163) P value
T1a
Disease-free 104 (86.0%) 139 (85.3%) 1.00
Overall recurrences 17 (14.0%) 24 (14.7) 1.00
Locoregional 7 (5.8%) 7 (4.3%) .59
Distant 10 (8.3%) 17 (10.4%) .68
Mean time to recurrence 19.7 23.8 .39
Segmentectomy
(n ¼ 57)
Lobectomy
(n ¼ 88) P value
T1b
Disease-free 48 (84.2%) 62 (64.7%) .074
Overall 9 (15.8%) 26 (29.5%)
Locoregional 3 (5.3%) 8 (9.0%) .53
Distant 6 (10.5%) 18 (20.5%) .17
Mean time to recurrence 28.9 23.4 .58
394 The Journal of Thoracic and Cardiovascular Surgthe pulmonary anatomy and pathology, many thoracic sur-
geons question the need for lobar resection of small lesions,
whichmay be easily resected with a ‘‘margin free’’ sublobar
approach. Certainly, image-guided interventionalists (ie, in-
terventional radiologists, radiation oncologists) and many
prospective patients are intrigued with the possibility of
less drastic/morbid clinically competitive ablative measures
that may be associated with preservation of normal pulmo-
nary parenchyma and potential clinical equivalency to
lobectomy.
The possible role of anatomic segmentectomy as an alter-
native to lobectomy in this clinical setting is intriguing and
certainly clinically competitive to image-guided ablative
approaches, particularly when segmentectomy can be
done using minimally invasive surgical approaches.7,12 In
addition, we should consider the primary arguments in
favor of a surgical resection of the small stage 1A lung
cancer over image-guided ablative approaches. These in-
clude complete resection of the cancer with clear surgical
margins determined by pathologic review; the ability to
supplement the local control of the disease with intraopera-
tive brachytherapy when surgical margins are close13; com-
prehensive lymph node staging of the malignancy to avoid
understaging of the disease and loss of the opportunity for
adjuvant systemic therapy for these understaged patients;
and pharmacogenomic testing of the tumor mass to provide
enhanced individualized systemic adjuvant therapy of the
patient’s disease.
The use of segmentectomy for the management of early-
stage NSCLC is not a new concept. Indeed, segmentectomy
for benign pulmonary conditions dates back several years.14
The use of this approach for early-stage NSCLC, first re-
ported in 1973 by Jensik and associates,15 was supported
by others over the ensuing 2 decades.16,17 Unfortunately,ery c February 2012
FIGURE 4. Cancer-specific survival curves comparing outcomes after segmentectomy or lobectomy for T1a (A) and T1b (B) tumors.
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on minimally invasive pulmonary surgery, most thoracic
surgeons are now not familiar with this pulmonary
parenchymal–sparing anatomic resection approach to
benign or malignant pulmonary disease.18
The analysis of our experiencewith anatomic segmentec-
tomy of both T1a and T1b tumors within the overarching
category of stage 1A NSCLC suggests that recurrence-
free and cancer-specific survivals are equivalent among pa-
tients undergoing anatomic segmentectomy or lobectomy.
Of course, careful mediastinal/hilar lymph node assessment
to optimize the validation of this pathologic stage 1A dis-
ease status is mandatory to prevent the exclusion of patients
with ‘‘surprise node positive’’ disease from the potential
benefits of adjuvant chemotherapy and the necessarily erro-
neous assumptions of our surgical results with supposed
stage 1A disease.19-21
Another point of analytic importance relates to the non–
cancer-related mortalities among patients with stage 1A
NSCLC in our experience. Non–cancer-related deaths
seem to more common among patients undergoing segmen-
tectomy as definitive surgical management for stage 1A
NSCLC, suggesting a continued selection bias in favor of
lobectomy among thoracic surgeons for patients free of sig-
nificant physiologic impairment.
So which direction are we to go with regard to the recom-
mendations for the small peripheral stage 1A NSCLC?
Should we be content in believing that lobectomy is the
best approach for stage 1 NSCLC in these times of compet-
itive pressures from nonsurgical image-guided approaches
to ‘‘early-stage’’ NSCLC?22 Whatever the future brings re-
garding persistence or changes in therapeutic paradigms,
we continue to recommend adherence to the primary surgi-
cal contentions of complete ‘‘R0’’ resection with negative
surgical margins and complete nodal staging of the malig-
nant disease.The Journal of Thoracic and CaCONCLUSIONS
Can we make the step forward away from the empirical
recommendation of lobectomy and possibly toward selec-
tive consideration for anatomic segmentectomy when ‘‘an-
atomically feasible’’ for the patient with peripheral stage
1A NSCLC? The results of our experience suggest this is
possible. However, the results of currently active prospec-
tive, randomized trials (Cancer and Leukemia Group B
140503) and possibly future ‘‘propensity matched trials’’
evaluating the utility of lobectomy compared with segmen-
tectomy (and for that matter, image-guided ablative ap-
proaches to stage 1A NSCLC) will direct the appropriate
clinical pathways for the ongoing management of early-
stage NSCLC.
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Discussion
Dr Paul Schipper (Portland, Ore). I appreciate what you and
your coauthors have done to evaluate the surgical treatment of
these early-stage tumors. Your historical data applied to the new
system get information out there quicker. However, you have to
be cautious when you are making prospective or clinical decisions
using retrospective pathologic data.
I have 2 questions for you based on the strong bias that exists
when you do this. When we are in the operating room, we are usu-
ally working with a combination of clinical and, if we are doing
our job right, pathologic data, but we do not have that final story.
We do not have the final pathology. Where most of the mystery
seems to lie, at least in my practice, is with the nodes that are in
the lung itself, the N1 nodes, the intraparenchymal nodes. So my
first question is, if I encounter a lesion, a 1.9-cm or T1a lesion,
and same question for a 2.5-cm or T1b lesion, N2 node negative,
good lung function, should I do a segment or a lobe? Before you
answer, if on that final pathology I find there are N1 nodes that
are positive and I did a segment, have I done the right operation?396 The Journal of Thoracic and Cardiovascular SurgDr Carr. Let’s start with the T1a lesion that is N2 negative. It is
our standard that we actually dissect out the N1 nodes associated
with the bronchovascular structures just before dividing them
and send them off as frozen. When we get those back and there
is a negative frozen section on that N1 lymph node, we then pro-
ceed immediately with an extended segmentectomy, as has been
mainly described in the Japanese literature (Okada). However, if
that N1 node comes back positive, we immediately assume there
may be additional disease we are missing, which would obviously
upstage that patient in terms of stage, and then proceed to lobec-
tomy. The same is true then for the T1b tumors. We have the
same approach to either patient. Identify N1 nodes, frozen section,
and then if positive, the patient undergoes lobectomy as opposed to
segmentectomy.
Dr Schipper.My second question then has to do with survivals.
In the Abstract, you gave us recurrence-free survival and then today
the additional information, which was very good, with the cancer-
specific survivals. Things became a little more homogeneous when
you went from one to the other. The trend that existed between bet-
ter survival with lobectomy (80%) and segmentectomy (67%) in
the T1b lesions, for example, disappeared when we looked at the
cancer-specific survival. As you pointed out, that had to do with
the fact that your patients undergoing segmentectomy were sicker.
Your comparison slide showed that very well. They had worse
FEV1, more chronic obstructive pulmonary disease, and more cor-
onary artery disease. You then proved the patients undergoing seg-
mentectomy were sicker by following them prospectively and
finding they died sooner than those undergoing lobectomy and of
cancer-unrelated causes. Because they died of these other things,
the segmentectomy cases did not have the same opportunity as
the lobectomy cases to die of lung cancer. It is a clinical decision
that we make when I evaluate somebody, and I say I don’t think
you are going to live much longer for cancer-unrelated reasons,
and therefore I am not going to give you what I perceive as the du-
rable operation, lobectomy; rather, I am going to give you a less du-
rable operation but one that is may be just as good for your specific
situation, and that is the segmentectomy.
Do your data show that segmentectomy is just as good or poten-
tially better for somebody who has a couple of decades left, some-
body who is not going to die of cancer-unrelated causes in the near
future?
Dr Carr. Initially when we started enrolling patients and seg-
mentectomies were performed, we were looking at patients who
had compromised lung function, and we were doing everything
we could to do a parenchymal-sparing operation to give them
the best quality of life and postoperative pulmonary function test
results. However, we have begun performing segmentectomies
on younger patients who have normal pulmonary function test re-
sults and are doing well. As you see, you are absolutely right, and it
is a limitation of looking at a retrospective database when you have
a difference in pulmonary function test results and the patients are
older, but the recurrence-free survival with a mean overall follow-
up overall of 45.3 months allows us to say that it is likely that a true
anatomic segmentectomy, and not just a sublobar resection but an
anatomic segmentectomy, is equivalent to a lobectomy in a patient
who has decades left to live.
DrFredericGrannis (Duarte, Calif). Thismeeting has had a re-
markable focus on health care policy and the science of health careery c February 2012
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Sdelivery, and this problem you have shown here is a casewhere you
can cure the overwhelming majority of lung cancers, but the cases
you are describing make up only 7% of all lung cancers in the
United States. Where did these cases come from? Did they come
from the screening program for computed tomography in Pitts-
burgh or from serendipity? Finally, when arewe going to stop wait-
ing for patients to develop symptoms of lung cancer, at which point
they are almost never curable, and move forward to have a health
care system where we proactively screen for these cancers?
Dr Carr.At Pittsburgh we do have a lung cancer screening pro-
gram (PLuSS) similar to the Early Lung Cancer Action Program
(Claudia Henschke) that does assist in identifying patients with
early-stage disease. In western Pennsylvania, there are only 2 large
institutions performing more advanced lung surgery like this, Al-
legheny and Pittsburgh, and Pittsburgh has more hospitals, so our
catchment is significantly higher. We are out in the community
working with the pulmonologists getting them to realize that we
do need to refer patients sooner and not wait. We’ll enroll them
in a screening process because they do have nodules, and we
will keep track of them. We have pulmonologists who are dedi-
cated and interested in just following these pulmonary nodules,
and when there are any changes they immediately refer them to us.
Your second question is a bit trickier. As time goes by, we will
be able to use screening tools, potentially genomic analysis, to risk
stratify patients as we get more robust data on screening programs
for lung cancer. However, I think we are all aware that with
changes in health care that may be coming down the pike and
the cost associated with this, we are going to need to find a cost-
effective way to screen. Until we find a cost-effective way to accu-
rately screen patients with good sensitivity and specificity, we are
still falling short. Hopefully those days are coming.
DrGrannis. I would just remind you that as time passes, 160,000
people die each year, and we do have a way to fund it, and that is
medical monitoring lawsuits against the tobacco industry.
Dr Thomas Rice (Cleveland, Ohio). I would like to propose an-
other conclusion to your study or an alternate: The best patients
with the worst cancer have a survival similar to the worst patients
with the best cancer. The problem is that this is a retrospective
study with significant bias in the selection of patients with similar
survival, which may be the result of that selection bias. To make
a fair comparison, you have to compare similar patients. ThisThe Journal of Thoracic and Caretrospective study would benefit immensely from propensity
scoring and then to compare matched groups. That would be ben-
eficial to your readers and a great addition to the literature.
Another comment is the lymph node harvest. People who un-
dergo VATS have a mean and standard deviation that are equal.
Those are skewed data, and it is better to present that as a median
plus a range. How did you handle that statistically to compare
those 2 groups? I think it has a bearing on recurrence.
Dr Carr. We agree that this is not level 1 evidence, and that
these findings will require validation by a prospective, randomized
study such as Dr Altorki’s trial (CALGB 140503).
As far as the lymph nodes are concerned, we have found that the
larger specimen associated with lobectomy produces higher lymph
node counts of final pathologic examination. The total number of
lymph node stations assessed was similar between the groups. Im-
portantly, there is no level 1 evidence to suggest that doing a more
aggressive lymph node dissection improves recurrence rates or
survival following lung resection, as demonstrated by the findings
of the ACOSOG Z0030 study.
Dr Joseph Shrager (Stanford, Calif). You end up concluding
that up to 3 cm is okay for a sublobar resection. There are a couple
of previous reports, I think you alluded to one of them, and I apol-
ogize that I do not remember where they each came from, with one
suggesting that the margin has to be at least as large as the diameter
of the tumor and one suggesting the margin has to be at least 2 cm.
You did not address anything about margins. Would you stand by
those sorts of recommendations? In other words, when is a sublo-
bar resection not appropriate?
Dr Carr. We have previously examined the issue of surgical
margins in the context of segmentectomy and found that the risk
of recurrence is diminished when surgical margin is greater than
the size of the tumor (magin:tumor ratio>1). So a 2-cm tumor
would ideally be served by a resection with a 2-cm margin. Inter-
estingly, in the current analysis we did not see any significant dif-
ference in surgical margin:tumor diameter ratios when comparing
lobectomy with segmentectomy for either T1a or T1b tumors, sug-
gesting that we are intuitively selecting the surgery that permits ad-
equate margins on an individual case-by-case basis. If we believe
that the surgical margin would be compromised with an anatomic
segmentectomy, than lobectomy should be preformed if the pa-
tient’s physiologic status permits.rdiovascular Surgery c Volume 143, Number 2 397
